Table 1.
Clinical evidence for DTAS in selected mothership patients.
| Author, year |
Type (R/NR) |
Number of patients |
Inclusion criteria | DTG (min) |
90-day mRS 0–2 |
Door to reperfusion |
Mimics DTAS (%) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DTAS | Control | DTAS | Control | DTAS | Control | DTAS | Control | ||||
| Psychogios et al., 2017¥[34] | Prospective (NR) | 21 | 33 | 1) First 5 h from known symptom onset 2) NIHSS ≥ 10 3) Patients were excluded if the angio suite was not available 4) Low-ASPECT, not a contraindication |
25 | 59 | N.A | N.A | 62 | 106 | 16% |
| Requena et al., 2020¥[35] | Retrospective (CC) | 50 | 175 | 1) First 6 h from known symptom onset 2) RACE scale ≥ 4 3) NIHSS > 10 4) Angio suite available |
16 | 70 | 29% | 43% | 65 | 113 | 32% |
| Pfaff et al., 2020°, ¥[36] | Prospective (R) | 26 | 34 | 1) NIHSS> 7 2) pre-stroke mRS ≤ 3 3) Angiosuite available |
41 | 40 | 61.5% | 76.5% | 80 | 78 | 13% |
| Requena et al., 2021¥[37] | Prospective (R) | 21 | 22 | 1) First 6 h from known symptom onset 2) RACE scale > 4 3) NIHSS > 10 4) pre-stroke mRS ≤ 2 5) Angio suite available |
18 | 42 | 43.6% | 28.8% | 57 | 84 | 16.9% |
¥ Heterogenous group of patients, including transfer patients, case number in the DTAS, and % of mimics refer to mothership patients only.
° mRS outcomes reported for 0–3 at 90-days.
NR: non-randomized; R: randomized, CC: case-control; DTAS: direct-to–angio suite; DTG: door-to-groin; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale;